Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8791270 | EAGLE PHARMS | Bendamustine pharmaceutical compositions |
Jan, 2026
(1 year, 7 months from now) | |
US9572796 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(6 years from now) | |
US9572797 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(6 years from now) | |
US11103483 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(6 years from now) | |
US11844783 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(6 years from now) | |
US10010533 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(6 years from now) | |
US11872214 | EAGLE PHARMS | Formulations of Bendamustine |
Jan, 2031
(6 years from now) | |
US9265831 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(6 years from now) | |
US8609707 | EAGLE PHARMS | Formulations of bendamustine |
Aug, 2031
(7 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
ODE*(ODE*) | Dec 07, 2022 |
Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 15 May, 2018
Treatment: For the treatment of patients with indolent b-cell non-hodgkin lymphoma; For the treatment of patients with chronic lymphocytic leukemia
Dosage: SOLUTION;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8791270 | EAGLE PHARMS | Bendamustine pharmaceutical compositions |
Jan, 2026
(1 year, 7 months from now) | |
US8791270 (Pediatric) | EAGLE PHARMS | Bendamustine pharmaceutical compositions |
Jul, 2026
(2 years from now) | |
US9265831 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(6 years from now) | |
US9572797 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(6 years from now) | |
US9572796 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(6 years from now) | |
US11103483 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(6 years from now) | |
US11844783 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(6 years from now) | |
US11872214 | EAGLE PHARMS | Formulations of Bendamustine |
Jan, 2031
(6 years from now) | |
US10010533 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(6 years from now) | |
US8609707 | EAGLE PHARMS | Formulations of bendamustine |
Aug, 2031
(7 years from now) | |
US10052385 | EAGLE PHARMS | Formulations of bendamustine |
Mar, 2033
(8 years from now) | |
US9144568 | EAGLE PHARMS | Formulations of bendamustine |
Mar, 2033
(8 years from now) | |
US9579384 | EAGLE PHARMS | Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration |
Mar, 2033
(8 years from now) | |
US9597399 | EAGLE PHARMS | Formulations of bendamustine |
Mar, 2033
(8 years from now) | |
US9572887 | EAGLE PHARMS | Formulations of bendamustine |
Mar, 2033
(8 years from now) | |
US9034908 | EAGLE PHARMS | Formulations of bendamustine |
Mar, 2033
(8 years from now) | |
US9000021 | EAGLE PHARMS | Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration |
Mar, 2033
(8 years from now) | |
US9597397 | EAGLE PHARMS | Formulations of bendamustine |
Mar, 2033
(8 years from now) | |
US9597398 | EAGLE PHARMS | Formulations of bendamustine |
Mar, 2033
(8 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE-179) | Dec 07, 2022 |
Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 07 December, 2015
Treatment: For use in treatment of patients with chronic lymphocytic leukemia (cll) and/or non-hodgkin's lymphoma; For the treatment of patients with indolent b-cell non-hodgkin lymphoma; For the treatment of pa...
Dosage: SOLUTION;IV (INFUSION)
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9604990 | EAGLE PHARMS | Crystalline forms of pemetrexed diacid and manufacturing processes therefor |
Oct, 2035
(11 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7772209 | EAGLE PHARMS | Antifolate combination therapies |
May, 2022
(1 year, 11 months ago) | |
US11793813 | EAGLE PHARMS | Pemetrexed formulations |
Feb, 2036
(11 years from now) |
Drugs and Companies using PEMETREXED ingredient
Market Authorisation Date: 08 February, 2020
Treatment: Use of pemetrexed with prior and/or repeated vitamin b12 and folic acid administration in patients with non-squamous non-small cell lung cancer
Dosage: SOLUTION;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9884044 | EAGLE PHARMS | Treatment using dantrolene |
Jun, 2022
(1 year, 11 months ago) | |
US8604072 | EAGLE PHARMS | Treatment using dantrolene |
Jul, 2022
(1 year, 9 months ago) | |
US8110225 | EAGLE PHARMS | Treatment using dantrolene |
Dec, 2022
(1 year, 4 months ago) | |
US8685460 | EAGLE PHARMS | Treatment using dantrolene |
Feb, 2023
(1 year, 3 months ago) | |
US7758890 | EAGLE PHARMS | Treatment using dantrolene |
Jun, 2025
(1 year, 1 month from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE) | Jul 22, 2021 |
Orphan Drug Exclusivity(ODE-69) | Jul 22, 2021 |
Drugs and Companies using DANTROLENE SODIUM ingredient
Market Authorisation Date: 22 July, 2014
Treatment: For use in the treatment of malignant hyperthermia in conjunction with appropriate supportive measures and for the prevention of malignant hyperthermia in patients at high risk.
Dosage: FOR SUSPENSION;INTRAVENOUS